-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alexion Pharma recently announced that the U.
Ultomiris is a long-acting C5 complement inhibitor that can inhibit the C5 protein in the complement cascade of the human immune system, and can provide immediate, complete and sustained complement inhibition
Since it was first approved in 2018, Ultomiris has quickly become the standard treatment for adult patients with PNH in the United States
Ultomiris is designed to inhibit the C5 protein in the terminal part of the complement cascade, while retaining the functions of other parts of the immune system to resist common pathogens and infections
This approval is based on the results of a phase 3 clinical study
Note: The original text has been deleted